“Real World” Administration of Zepatier (Grazoprevir plus Elbasvir in Chronic Hemodialysis Patients with Hepatitis C Infection. Strategies for Identification of Candidate Hemodialysis Patients, Obtainment of Insurance Approval, Treatment Guidelines, and Laboratory and Clinical Monitoring During Therapy Directed to Nephrologists

The purpose of this study is to learn how to dialysis doctors can treat dialysis patients infected with Hepatitis C themselves. Hepatitis C infection is common in hemodialysis patients. There are new medications, such as Zepatier, which can cure hepatitis C in > 95% of patients. Zepatier is particularly good for hemodialysis patients with Hepatitis C since the drug is eliminated by the liver and not the kidney. Zepatier is currently approved by the Food and Drug Administration (FDA) to treat certain types of hepatitis C in dialysis patients. For most patients with hepatitis C, one pill per day of Zepatier for 12 weeks will be sufficient. However, there may be so patients who may require 16 weeks of therapy or the addition of another FDA approved drug called Ribavirin. If you need 16 weeks of treatment or the addition of Ribavirin you will be told at the screening visit. Routine testing of all the patients in your dialysis unit, has identified patients such as yourself, with blood studies that demonstrate a hepatitis C infection. If you choose to participate in this study, other testing will be done to see if you qualify. If you do qualify, you will be provided medication for treatment of your hepatitis C at no cost.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  hep c, hepatitis C
• Age: Between 18 Years - 80 Years
• Gender: All